A Study to Compare Quality of Life and Compliance in Patients Receiving High-dose Interferon Versus Pegylated Interferon in Patients With Surgically Resected Melanoma
An Observational Pilot Study to Compare the Compliance With and Health Related Quality of Life During Therapy With Standard High-Dose Interferon Alfa (Intron A, HDI) Versus Pegylated Alfa-Interferon 2b (Sylatron, PEG IFN) in Patients With Surgically Resected Melanoma
Sponsor: Merck Sharp & Dohme LLC
A observational or N/A phase clinical study on Melanoma, this trial is completed. The trial is conducted by Merck Sharp & Dohme LLC and has accumulated 11 data snapshots since 2013. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
11 versions recorded-
Mar 2025 — Present [monthly]
Completed
Status: Unknown → Completed
-
Sep 2024 — Mar 2025 [monthly]
Unknown
-
Jul 2024 — Sep 2024 [monthly]
Unknown
Status: Unknown Status → Unknown
-
Jun 2022 — Jul 2024 [monthly]
Unknown Status
-
Apr 2022 — Jun 2022 [monthly]
Unknown Status
Status: Active Not Recruiting → Unknown Status
▶ Show 6 earlier versions
-
Jan 2021 — Apr 2022 [monthly]
Active Not Recruiting
-
Jun 2018 — Jan 2021 [monthly]
Active Not Recruiting
-
May 2018 — Jun 2018 [monthly]
Active Not Recruiting
Status: Recruiting → Active Not Recruiting
-
Apr 2018 — May 2018 [monthly]
Recruiting
Phase: NA → None
-
Jul 2017 — Apr 2018 [monthly]
Recruiting NA
-
Jan 2017 — Jul 2017 [monthly]
Recruiting NA
First recorded
Dec 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Merck Sharp & Dohme LLC
- St. Luke's Hospital and Health Network, Pennsylvania
For direct contact, visit the study record on ClinicalTrials.gov .